Rhumbline Advisers Has $60.10 Million Stake in Boston Scientific Corporation (BSX)

Rhumbline Advisers grew its position in Boston Scientific Corporation (NYSE:BSX) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,424,300 shares of the medical equipment provider’s stock after acquiring an additional 54,174 shares during the period. Rhumbline Advisers’ holdings in Boston Scientific were worth $60,098,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Boston Scientific by 2.7% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 44,496 shares of the medical equipment provider’s stock valued at $1,233,000 after acquiring an additional 1,178 shares in the last quarter. Nippon Life Insurance Co. boosted its holdings in Boston Scientific by 2.8% during the third quarter. Nippon Life Insurance Co. now owns 62,876 shares of the medical equipment provider’s stock worth $1,834,000 after buying an additional 1,733 shares in the last quarter. Brown Advisory Inc. boosted its holdings in Boston Scientific by 3.0% during the third quarter. Brown Advisory Inc. now owns 60,451 shares of the medical equipment provider’s stock worth $1,763,000 after buying an additional 1,771 shares in the last quarter. Moors & Cabot Inc. boosted its holdings in Boston Scientific by 3.7% during the third quarter. Moors & Cabot Inc. now owns 49,975 shares of the medical equipment provider’s stock worth $1,468,000 after buying an additional 1,800 shares in the last quarter. Finally, Private Wealth Partners LLC boosted its holdings in Boston Scientific by 0.9% during the third quarter. Private Wealth Partners LLC now owns 209,870 shares of the medical equipment provider’s stock worth $6,122,000 after buying an additional 1,819 shares in the last quarter. 89.84% of the stock is currently owned by institutional investors and hedge funds.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at $27.20 on Friday. Boston Scientific Corporation has a fifty-two week low of $23.29 and a fifty-two week high of $29.93. The stock has a market cap of $37,350.93, a PE ratio of 21.59, a price-to-earnings-growth ratio of 1.97 and a beta of 0.81. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.34. Boston Scientific had a net margin of 1.15% and a return on equity of 24.04%. The company had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.39 billion. During the same quarter in the prior year, the firm earned $0.30 earnings per share. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. equities research analysts expect that Boston Scientific Corporation will post 1.37 EPS for the current fiscal year.

A number of research firms recently commented on BSX. Jefferies Group reissued a “neutral” rating on shares of Boston Scientific in a report on Friday, February 2nd. Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th. TheStreet raised shares of Boston Scientific from a “c+” rating to a “b” rating in a report on Thursday, January 18th. Canaccord Genuity reissued a “buy” rating on shares of Boston Scientific in a report on Wednesday, January 17th. Finally, Needham & Company LLC reissued a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Boston Scientific presently has a consensus rating of “Buy” and an average price target of $31.00.

In other Boston Scientific news, SVP David A. Pierce sold 5,152 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total value of $139,104.00. Following the sale, the senior vice president now owns 38,116 shares of the company’s stock, valued at $1,029,132. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David A. Pierce sold 8,763 shares of the company’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $27.74, for a total transaction of $243,085.62. Following the completion of the sale, the senior vice president now directly owns 24,201 shares in the company, valued at approximately $671,335.74. The disclosure for this sale can be found here. Insiders sold 177,032 shares of company stock worth $4,648,733 in the last ninety days. Insiders own 0.74% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Rhumbline Advisers Has $60.10 Million Stake in Boston Scientific Corporation (BSX)” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/18/rhumbline-advisers-has-60-10-million-stake-in-boston-scientific-corporation-bsx.html.

Boston Scientific Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply